iPierian has filed a patent in Canada claiming intellectual property rights for its iPS technology. iPierian has already obtained similar patent rights in Japan and has a patent pending in the US.
Along with the surge of iPS-based drug discovery and therapeutic approaches, there is mounting concern over the patenting of biological materials. It will be interesting to see what happens in the commercial iPS cell world and the larger arena of biomaterial-based therapies, particularly given the recent federal ruling barring the patenting of genes in the US (http://www.nytimes.com/2010/10/30/business/30drug.html?_r=1).
Click here to read more.Share this: